MEDIA ADVISORY – Oncolytics Biotech® Inc. Announces Participation in the Canaccord Genuity 36th Annual Growth Conference Read More
Oncolytics Biotech® Inc. Reports Additional Data from Randomized Phase II Study of REOLYSIN® in Non-Small Cell Lung Cancer Read More
Exploring REOLYSIN®’s Objective Response Rate in Females with Colorectal Cancer Read More
Did you catch our presentation at the Canaccord Genuity Growth Conference last month? Watch the webcast here: https://t.co/jDgeqISoIz.
Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus https://t.co/cMKVoxkrnu via @AACR